Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840962 | 0.90 | SIGMAR1 (0.43) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL5175065 | 0.82 | MAPK1 (0.49) | CHRM1KMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL5842304 | 0.80 | SIGMAR1 (0.54) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL12881451 | 0.79 | TP53 (0.47) | SIGMAR1CHRM1KMT2AALDH1A1POLB | |
| SCHEMBL1206706 | 0.77 | TP53 (0.39) | CHRM1KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL12881438 | 0.76 | TP53 (0.47) | CHRM1ALDH1A1TSHRMAPK1 | |
| SCHEMBL23023818 | 0.76 | SIGMAR1 (0.50) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL19677041 | 0.76 | SIGMAR1 (0.50) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL8735577 | 0.76 | ALDH1A1 (0.50) | KMT2AALDH1A1POLBTSHRMAPK1 | |
| SCHEMBL8957048 | 0.75 | LMNA (0.49) | SIGMAR1CHRM1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992085-B2 | Octahydro-2H-pyrido[1,2-a]pyrazine compounds | LES LABORATORIES SERVIER (FR) | 2006-01-31 | — | — | US | disclosed |
| CN-1197863-C | NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them | SERVIER LAB (FR) | 2005-04-20 | — | — | CN | disclosed |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-10-16 | — | — | US | disclosed |
| CN-1397557-A | NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them | SAVOIREN LAB (FR) | 2003-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | CYP2W1, OXER1, IL1R1 | SIGMAR1 47/4885CHRM5 219/4885CHRM1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.